mirage

Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Santos-Lozano, Alejandro
dc.contributor.author Morales González, A.
dc.contributor.author Sanchís-Gomar, Fabián
dc.contributor.author Cristi Montero, Carlos
dc.contributor.author Fiuza Luces, María del Carmen
dc.contributor.author Pareja Galeano, Helios
dc.contributor.author Martínez López, Joaquín
dc.contributor.author Garatachea, Nuria
dc.contributor.author Lucía Mulas, Alejandro
dc.date.accessioned 2016-09-21T07:53:51Z
dc.date.available 2016-09-21T07:53:51Z
dc.date.issued 2016
dc.identifier.citation Santos-Lozano, A., Morales-González, A., Sanchís-Gomar, F., Cristi-Montero, C., Fiuza-Luces, C., Pareja-Galeano, H., ... & Lucía, A. (2016). Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials. Critical Reviews in Oncology/Hematology, 105, 118-126. DOI: 10.1016/j.critrevonc.2016.06.004 spa
dc.identifier.issn 10408428
dc.identifier.uri http://hdl.handle.net/11268/5794
dc.description.abstract Waldenström macroglobulinemia (WM) is a malignant lymphoproliferative disorder characterized by the presence of a high level of serum monoclonal IgM and a lymphoplasmacytic infiltrate in the bone marrow. This meta-analysis sought to assess the effectiveness of the different treatments for WM tested in published trials using the response rate (RR) as the main outcome measure. Forty-six articles (1409 patients) identified were entered in a variable effects model meta-analysis of proportions (rates and sample sizes). A greater response to treatment was produced in patients treated with a combination of 2+ drugs (RR=73%; 95%CI: 62, 83; p<0.01) than in those receiving monotherapy with rituximab (RR=44%; 95%CI: 34, 55; p<0.01) or a purine analogue [61% (95%CI: 43, 78; p<0.01) for cladribine and 53% (95%CI: 34, 72; p<0.01) for fludarabine]. The combination rituximab+cladribine emerged as particularly effective (RR=87%; 95%CI: 78, 94; p<0.01), slightly more effective than rituximab+bortezomib/dexamethasone (RR=84%; 95%CI: 79, 88; p<0.01) and rituximab+cyclophosphamide/dexamethasone [RR=81% (95%CI: 72, 88; p<0.01)]. Our results are in overall agreement with treatment recommendations from the seventh International Workshops on WM. Our findings are limited by the fact that we could not analyze progression-free survival (PFS). More phase II/III trials are needed to corroborate promising recent findings with bendamustine and carfilzomib and further research are needed to standardize recommendations based on maximum treatment efficacy combined with lowest toxicity, differentiation between first vs second line treatment, or long-term follow up after treatment. spa
dc.description.sponsorship SIN FINANCIACIÓN spa
dc.language.iso eng spa
dc.title Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials spa
dc.type article spa
dc.description.impact 4.971 JCR (2016) Q1, 50/217 Oncology, 16/70 Hematology spa
dc.identifier.doi 10.1016/j.critrevonc.2016.06.004
dc.rights.accessRights openAccess spa
dc.subject.uem Linfomas spa
dc.subject.uem Oncología spa
dc.subject.unesco Cáncer spa
dc.description.filiation UEM spa
dc.peerreviewed Si spa


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record